secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2024-10-02T23:59:59+00:00
Accession:  0001193125-24-230760
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera expands atacicept program to broader IgAN and autoimmune kidney diseases with two new studies
--------------------------------------------------------------------------------

- ORIGIN Extend to start Q4 2024, providing extended atacicept access and long-term data for ORIGIN participants.
- PIONEER study in 2025 will evaluate atacicept in expanded IgAN populations (low eGFR, high/low proteinuria, recurrence post-transplant, adolescents) and podocytopathies (pMN, FSGS, MCD).
- Combined US peak prevalence of IgAN and autoimmune-driven pMN, FSGS, MCD estimated at ~230,000.
- 96-week Phase 2b ORIGIN data to be presented as Late Breaking Oral at ASN Kidney Week 2024.
- Multiple regulatory and clinical milestones expected over next 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312524230760/0001193125-24-230760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312524230760/d802938d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-230760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer